Renalytix plc — fact timeline

Daniel Levangie resigned as Non-Executive Director at Renalytix plc.

“Daniel Levangie, tendered his resignation from the Company's Board of Directors and all committees effective on October 31, 2024.”

Joel R. Jung was appointed as Interim Chief Financial Officer at Renalytix plc.

“announcing the appointment, on May 27, 2024, of Joel R. Jung as Interim Chief Financial Officer of the Company in connection with O. James Sterling’s resignation from his position with the Company.”

O. James Sterling resigned as Chief Financial Officer at Renalytix plc.

“announcing the appointment, on May 27, 2024, of Joel R. Jung as Interim Chief Financial Officer of the Company in connection with O. James Sterling’s resignation from his position with the Company.”

Joel R. Jung was appointed as Interim Chief Financial Officer at Renalytix plc.

“On May 27, 2024, the board of directors (the “ Board ”) of the Company appointed Joel R. Jung as Interim Chief Financial Officer and designated Mr. Jung as the Company’s principal financial officer and principal accounting officer, effective as of May 28, 2024.”

O. James Sterling resigned as Chief Financial Officer at Renalytix plc.

“On May 24, 2024, O. James Sterling tendered his resignation from his position as the Chief Financial Officer of Renalytix plc (the “ Company ”).”

Renalytix plc entered into Sales Agreement with H.C. Wainwright & Co., LLC valued at up to $15 million (effective 2024-05-15).

“On May 15, 2024, Renalytix plc (the “ Company ”) entered into an at the market offering agreement (the “ Sales Agreement ”) with H.C. Wainwright & Co., LLC (the “ Agent ”), pursuant to which the Company may issue and sell from time to time, at its option, the Company’s American Depositary Shares (the “ ADSs ”), each representing two ordinary shares (nominal value £0.0025 per share) of the Company, through or to the Agent, as sales agent and/or principal.”

Renalytix plc reported the fiscal third quarter ended March 31, 2024 results: revenue $0.5 million, net income Net loss was $7.7 million.

“During the three months ended March 31, 2024, the Company recognized $0.5 million of revenue, compared to $0.7 million for the three months ended March 31, 2023.”

Renalytix plc entered into Placing Agreement with Stifel Nicolaus Europe Limited valued at up to an aggregate of 46,801,872 ordinary shares (effective 2024-03-12).

“on March 12, 2024, Renalytix plc (the “ Company ”) entered into a Placing Agreement (the “ Placing Agreement ”) with Stifel Nicolaus Europe Limited”

Renalytix plc shareholders approved Authorization of disapplication of pre-emption rights limited to shares of maximum aggregate nominal amount of £128,391 at the 2024-04-22 meeting.

“Proposal 4 – Subject to and conditional upon the passing of Proposal 2, to authorize the disapplication of pre-emption rights limited to shares of a maximum aggregate nominal amount of £128,391. For Against Vote Withheld 45,853,622 4,859,914 120,004”

Renalytix plc shareholders approved Authorization of disapplication of statutory pre-emption rights for Second Tranche Placing Shares and shareholder approval pursuant to Nasdaq 20% Rule at the 2024-04-22 meeting.

“Proposal 3 – Subject to and conditional upon the passing of Proposal 1, to authorize (i) the disapplication of statutory pre-emption rights for the issue and allotment of the Second Tranche Placing Shares and (ii) shareholder approval pursuant to the Nasdaq 20% Rule. For Against Vote Withheld 50,072,092 641,404 120,044”

Renalytix plc shareholders approved Authorization of allotment of shares and grant of rights to subscribe for or convert into shares up to aggregate nominal amount of £128,391 and further allotment in connection with pre-emptive offer at the 2024-04-22 meeting.

“Proposal 2 – To authorize the allotment of shares and the grant of rights to subscribe for, or convert any security into, shares of the Company up to an aggregate nominal amount of £128,391 and the allotment of further equity securities up to an aggregate nominal amount of £122,277 in connection with a pre-emptive offer in favor of shareholders. For Against Vote Withheld 45,880,130 4,832,979 120,431”

Renalytix plc shareholders approved Authorization of allotment of ordinary shares up to aggregate nominal amount of £67,039.6025 (Second Tranche Placing Shares) at the 2024-04-22 meeting.

“Proposal 1 – To authorize the al lotment of ordinary shares of £0.0025 each in the capital of the Company up to an aggregate nominal amount of £67,039.6025 (26,815,841 ordinary shares) (the “Second Tranche Placing Shares”). For Against Vote Withheld 50,091,780 621,329 120,431”

Renalytix plc entered into Purchase Agreement with DB Capital Partners Healthcare, L.P. (effective 2024-04-05).

“on April 5, 2024, Renalytix plc (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with DB Capital Partners Healthcare, L.P. (the “ Purchaser ”)”

Howard Doran was appointed as President at Renalytix plc.

“On April 23, 2024, the Company’s Board of Directors (the “ Board ”) appointed Howard Doran, currently the Company’s Chief Business Officer, to serve as the Company’s President, effective as of April 30, 2024.”

Thomas McLain resigned as President at Renalytix plc.

“On April 17, 2024, Thomas McLain notified the Company that he will resign as President of the Company, effective April 30, 2024”

Renalytix plc amended Bond Agreement Amendment with CVI Investments, Inc. (effective 2024-03-28).

“On March 28, 2024, Renalytix plc (the “ Company ”) entered into a second amendment and restatement agreement (“ Bond Agreement Amendment ”) with CVI Investments, Inc. (" CVI "), which amended the terms of the Company’s existing bond agreement”

Renalytix plc entered into Placing Agreement with Stifel Nicolaus Europe Limited valued at up to an aggregate of 46,801,872 ordinary shares (effective 2024-03-12).

“On March 12, 2024, Renalytix plc (the “ Company ”) entered into a Placing Agreement (the “ Placing Agreement ”) with Stifel Nicolaus Europe Limited (the “ Bookrunner ” or “ Stifel ”), pursuant to which the Company agreed to allot and issue new ordinary shares, nominal value £0.0025 per ordinary share (the “ Placing Shares ”) to certain investors (the “ Placees ”) in an unregistered offering (the “ Private Placement ”), up to an aggregate of 46,801,872 ordinary shares.”